Canaan Partners

Canaan is an early-stage venture capital firm that 'invests in visionaries with transformative ideas' across a deliberate 60/40 technology-to-healthcare split. On the technology side, the firm targets enterprise SaaS, fintech, consumer, frontier tech (robotics, AI/ML, autonomous vehicles, supply chain), and cybersecurity. On the healthcare side, Canaan focuses on biopharma company creation and early investments in oncology, immunology, neurology, cardiology, and respiratory — including de novo company formation alongside experienced scientific teams. Canaan XIII ($650M fund closed April 2023, plus $200M in follow-on reserves) continues the firm's 35-year history of partnering with founders at seed and Series A, with reserves to support companies through IPO or M&A. The firm runs a transparent, debate-driven partnership process and prides itself on being 'the very first to partner with the best entrepreneurs' for the long haul, bringing 130 years of combined operating experience and a diverse team (40% women GPs, 47% immigrants or first-generation Americans).